SCHEMBL1000609

SCHEMBL1000609

CC(C)c1ccc(NC(=O)c2cccc(Cl)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.59
RAB9A P51151 7/20 0.59
SMN1; SMN2 Q16637 7/20 0.59
TP53 P04637 3/20 0.59
POLB P06746 2/20 0.59
ALDH1A1 P00352 2/20 0.59
HPGD P15428 1/20 0.59
MAPT P10636 3/20 0.56
LMNA P02545 2/20 0.56
GAA P10253 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
MAPK1 P28482 1/20 0.54
RECQL P46063 1/20 0.54
MCL1 Q07820 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15575804 0.82 POLB (0.79) NPC1RAB9ASMN1; SMN2POLBALDH1A1
SCHEMBL3158213 0.81 MAPT (0.67) NPC1RAB9ASMN1; SMN2POLBALDH1A1
SCHEMBL3831832 0.80 JAK2 (0.61) NPC1RAB9ASMN1; SMN2POLBALDH1A1
SCHEMBL30077014 0.80 JAK2 (0.61) NPC1RAB9ASMN1; SMN2POLBALDH1A1
SCHEMBL1003366 0.79 SMN1; SMN2 (0.53) NPC1RAB9ASMN1; SMN2TP53POLB
SCHEMBL1001053 0.78 POLB (0.50) NPC1RAB9ASMN1; SMN2TP53POLB
SCHEMBL28386072 0.78 CTSA (0.54) NPC1RAB9ASMN1; SMN2POLBALDH1A1
SCHEMBL15347281 0.77 POLB (0.51) NPC1RAB9ASMN1; SMN2TP53POLB
SCHEMBL30077159 0.77 POLB (0.51) NPC1RAB9ASMN1; SMN2TP53POLB
SCHEMBL9269873 0.77 MAPT (0.60) NPC1RAB9ASMN1; SMN2POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
CN-102015638-A Long-chain fatty acid elongase inhibitor containing arylsulfonyl derivative as active ingredient BANYU PHARMA CO LTD 2011-04-13 CN disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 NPC1 899/4885RAB9A 3688/4885SMN1; SMN2 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.